Cancer BiologybioRxiv
Preclinical Characterization of Relatlimab, a Human LAG-3-Blocking Antibody, Alone or in Combination With Nivolumab
K. Thudium, M. Selby, J. A. Zorn…·A. J. Korman
This paper characterizes relatlimab, a LAG-3-blocking antibody, showing it enhances anti-tumor activity when combined with nivolumab in preclinical models and is well-tolerated in monkeys.
DOI 10.1158/2326-6066.cir-22-0057